About The Foundation

Just a few years ago, a person diagnosed with Choroideremia was given little information about CHM, told there was little research going on, and no hope for a viable treatment or cure. Due to funding provided by the CRF, this outlook has changed. Now, it is no longer a question of “if” a treatment or cure can be found, it is now a question of “when.”

Board of Directors

Choroideremia (CHM) is a rare inherited disorder that causes progressive vision loss, ultimately leading to complete blindness. The first symptom is generally night-blindness, followed by vision loss in the mid-periphery. These “blind spots” appear in an irregular ring, only leaving patches of peripheral vision, while central vision is still maintained.

Science Advisory Board

The Science Advisory Board functions in two major capacities on behalf of the Choroideremia Research Foundation. The Science Advisory Board reviews all applications for research funding submitted to the CRF, providing thorough and diligent peer review. In addition, the Science Advisory Board will be tasked with periodically updating the Foundation on current and future avenues toward treatments for Choroideremia patients as the scientific landscape continues to progress and evolve.

News and Updates

Sign up to keep updated on the latest news, events, and research.

Tell Your Friends About Choroideremia

The Choroideremia Research Foundation Inc. is an international, non-profit organization dedicated to raising funds to find a treatment or cure for Choroideremia, a rare inherited retinal degenerative disease that causes blindness.

Copyright © 2017 The Choroideremia Research Foundation Inc.

The Choroideremia Research Foundation takes seriously our responsibility to maintain your privacy in all matters related to the Foundation. Specifically, we do not sell, rent or otherwise distribute to any individual or organization names, addresses or other information we receive through our newsletter, our website or other forms of digital or written communication.